CD8A and cancer: Current findings on the model of mice bearing LLC have suggested that co-treatment OMT with DDP significantly enhanced the CD8+/Treg ratio in comparison with single agent groups, which is also in agreement with other clinical evidence that decreased CD8+/Treg ratio among tumor infiltrating lymphocytes are correlated with poor prognosis in various types of human cancers (38–40).